2 results
Approved WMOCompleted
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
Approved WMOCompleted
Primary: To determine the MTD and/or RDE of LGH447 with or without midostaurin. Secondary: 1. To characterize the safety and tolerability of LGH447 with or without midostaurin at the MTD and/or RDE.2. To assess any observed antitumor activity of…